Abstract
Asymptomatic bacteriuria (ASB) is a common finding in many populations, including healthy women and persons with underlying urologic abnormalities. The 2005 guideline from the Infectious Diseases Society of America recommended that ASB should be screened for and treated only in pregnant women or in an individual prior to undergoing invasive urologic procedures. Treatment was not recommended for healthy women; older women or men; or persons with diabetes, indwelling catheters, or spinal cord injury. The guideline did not address children and some adult populations, including patients with neutropenia, solid organ transplants, and nonurologic surgery. In the years since the publication of the guideline, further information relevant to ASB has become available. In addition, antimicrobial treatment of ASB has been recognized as an important contributor to inappropriate antimicrobial use, which promotes emergence of antimicrobial resistance. The current guideline updates the recommendations of the 2005 guideline, includes new recommendations for populations not previously addressed, and, where relevant, addresses the interpretation of nonlocalizing clinical symptoms in populations with a high prevalence of ASB.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E83-E75 |
| Journal | Clinical Infectious Diseases |
| Volume | 68 |
| Issue number | 10 |
| DOIs | |
| State | Published - May 1 2019 |
Funding
potential conflicts of interest is determined by a review process that includes assessment by the Standards and Practice Guideline Committee (SPGC) Chair, the SPGC liaison to the development panel and the Board of Directors liaison to the SPGC, and if necessary, the Conflicts of Interests (COI) Task Force of the Board. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. S. F. B. has received research grants from the National Institutes of Health (NIH), the Veterans Affairs (VA) Cooperative Studies Program, the VA Health Services Research and Development Service (HSR&D)/CREATE, the VA/Centers for Disease Control and Prevention (CDC) Network, and Pfizer. D. D. has served as a consultant for Tetraphase and received research grants from VA Clinical Science Research and Development Merit Review, and the VA Cooperative Studies Program. K. G. has served as a consultant for Paratek, Ocean Spray, Iterum, and Tetraphase and has received other remuneration from UpToDate. S. G. has served as a consultant for Nordic Pharma. T. M. H. has served as a consultant for Damone, Melnata, Melinta OM Pharma, GlaxoSmithKline (GSK), Ocean Spray, Paratek, Shionogi, Achaogen, and Cubist; has ownership interest in Fimbrion Therapeutics; and has received other remuneration from Fimbrion Therapeutics and UpToDate. M. J. M. has received research grants from the NIH and has served as a consultant to Iterum Therapeutics. B. K. has received research grants from the European Association of Urology and served as a consultant for F. Hoffmann-La Roche Ltd. L. N. has served as a consultant for Paratek, Tetraphase, Utility, and GSK. R. S. is a member of the GRADE Working Group. S. S. has received research grants and contracts from the Department of Veterans Affairs, American Hospital Association, European Commission, NIH, CDC, and Agency for Healthcare Research and Quality (AHRQ); has received honoraria from Doximity and numerous individual hospitals and nonprofit organizations to discuss infection prevention, leadership, and patient safety; has ownership interest in Doximity and Jvion; and has a patent pending. B. T. has received research grants from VA HSR&D, AHRQ, CDC, NIH, and Zambon Pharmaceuticals, and one-time consulting fees from Paratek and Zambon Pharmaceuticals. B. W. has received research grants from Vifor; has served as a consultant for Vifor, Bionorica, and Leo Pharma; and has received honoraria from Vifor, Binorica, Astellas, and Leo Pharma. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Keywords
- Asymptomatic bacteriuria
- Bacteriuria
- Cystitis
- Diabetes
- Endourologic surgery
- Long-term care
- Neurogenic bladder
- Nursing home
- Older adults
- Pregnancy
- Pyelonephritis
- Renal transplant
- Spinal cord injury
- Urinary catheter
- Urinary tract infection
- Urologic devices
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
